Metformin as a Therapeutic Agent for Obesity-Associated Immune Dysfunction

Area of Science:

• Immunology
• Metabolic Disease Research
• Pharmacology

Background:

• Obesity is linked to chronic inflammation and immune dysfunction, increasing risks for infections, autoimmune diseases, and cancer.
• Immune deficits in obesity may persist even after weight loss, necessitating novel therapeutic strategies.
• Targeting obesity-associated inflammation is crucial for improving health outcomes.

Purpose of the Study:

• To review the potential of metformin as a therapeutic agent for obesity-associated immune dysfunction.
• To explore the immunomodulatory effects of metformin in the context of obesity.
• To summarize the evidence supporting metformin's role in mitigating obesity-related immune impairments.

Main Methods:

• Review of existing scientific literature on metformin's effects on the immune system in obesity.
• Analysis of studies investigating metformin's impact on immune cell function and cytokine production.
• Examination of evidence for both AMP-activated protein kinase (AMPK)-dependent and independent mechanisms.

Main Results:

• Metformin exhibits immunomodulatory properties, affecting immune responses in a cell- and disease-specific manner.
• Evidence suggests metformin enters immune cells, disrupting electron transport and influencing immune cell differentiation and cytokine profiles.
• Metformin's actions on immune cells have demonstrated potential benefits in infection, autoimmunity, and cancer models.

Conclusions:

• Metformin may serve as a viable therapeutic option to counteract obesity-induced immune dysfunction and inflammation.
• Further research into metformin's precise mechanisms of action on the immune system is warranted.
• Metformin's immunomodulatory effects offer a promising avenue for improving health in individuals with obesity-related complications.